MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings
|
|
- Emery Casey
- 5 years ago
- Views:
Transcription
1 MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018
2 Agenda MHRA inspections How inspectors use the PSMF Overview MHRA GVP Inspection Metrics Overview of MHRA GVP Inspection Metrics Common PSMF inspection findings PSMF inspection readiness Summary Group discussion Questions
3 MHRA Inspections MHRA inspections are conducted to examine compliance with existing EU and national pharmacovigilance regulations and guidelines. Good pharmacovigilance practice (GPvP) is the minimum standard for monitoring the safety of medicines on sale to the public in the EU. MHRA inspects marketing authorisation holders (MAH) and their contractors, to ensure they: ü Have an adequate and effective quality system for monitoring the medicines they have licences for ü Maintain a pharmacovigilance system master file ü Document all actions they take ü Have enough competent, appropriately qualified and trained staff to work the system
4 How the PSMF is used in inspections PSMF is usually requested when the MAH is notified of inspection by the MHRA. MHRA can request the MAH to provide the PSMF within 7 days or immediately. PSMF is an important document for gaining a better understanding of the organization and for inspection planning. It helps the inspectors to map out the scope and length of the inspection.
5 Inspection readiness PSMF To inform risk assessment, scope and for preparation Complete and accurate, whenever requested / submitted Advance document requests To address gaps in the PSMF, to allow inspectors to refine the scope of specific areas and prepare Expect to provide documents from inspection announcement, and before on-site dates Planning /Agenda discussions To clarify scope and ensure that facilities/ people will be available Be prepared to discuss the contribution of third parties, relevant staff and logistics Document provision Records and information to navigate the system and evidence of compliant activity Discuss, rather than infer, be prepared to provide records, increasing can be remotely inspected MHRA Symposium (2018), Changing the face of inspections
6 Inspection Metrics Year No. Inspections conducted April 2017-March April March April 2015-March There is been a significant decrease in the number of inspections between April March 2017 to April 2017-March 2018 (15 less inspections conducted)
7 Inspection Metrics: Critical findings April 2017-March *4 critical findings reported vs 6 in Signal Management Risk Management Supervision and Oversight Provisional data not all 2017/18 inspections have been closed. 1 critical finding reported in every 7 inspections vs 1 on 6 in Graph to show number critical findings April 2017-March 2018 MHRA symposium (2018), Inspection finding trends
8 Inspection Metrics: Critical findings April 2016-March critical findings reported vs 11 in Reduction in critical findings could indicate that significant issues identified at previous inspections were found to have been largely resolved during re-inspection or that there has been a positive trend toward compliance more generally. Graph to show number critical findings April 2016-March 2017 MHRA GPvP Inspection Metrics: April 2016 March 2017 It could also be indicative of the fact that the inspection programme in April 2016 to March 2017 mainly included routine, rather than targeted, inspections. 1 critical finding reported in every 6 inspections vs 1 in 3 in
9 Inspection Metrics: Critical findings April 2012-March 2018 Graph to show number critical findings April 2012-March 2018 MHRA symposium (2018), Inspection finding trends
10 Critical findings reported over time The graph below displays the average number of critical findings reported per inspection over time: MHRA GPvP Inspection Metrics: April 2016 March 2017 See next slide for summary of the graph
11 Summary of critical findings reported over time Average number of critical findings has decreased in the past two years. Average number of critical findings identified per inspection in this reporting period is 0.16 (rounded up to 0.2 in the graph), compared to 0.3 in the previous reporting period. This translates to a critical finding being reported approximately every six inspections on average, compared to every three inspections on average in the previous reporting period.
12 Inspection Metrics: Major findings April 2016-March major findings reported from 37 inspections Graph to show number major findings April 2016-March 2017 per inspected organisation MHRA symposium (2018), Inspection finding trends 1
13 Inspection Metrics: Major findings April 2016-March 2017 Graph displays the distribution of major findings by topic area 12 major findings in relation to PSMF MHRA GPvP Inspection Metrics: April 2016 March 2017
14 Inspection Metrics: Minor findings April 2016-March 2017 The chart below displays the distribution of minor findings by topic area o 84 minor findings were identified during the reporting period o Largest proportion of minor findings was in relation to the PSMF MHRA GPvP Inspection Metrics: April 2016 March 2017
15 PSMF examples affecting inspection days Information required Details Complete clinical trial listings PASS including investigator initiated studies Countries of sites PV activities undertaken by third parties Complete list of SOP, audits, CAPA and deviations Coverage of local (national) obligations Inclusion of content from non Drug Safety departments relevant to PV activities (e.g. medical affairs, clinical operations, regulatory affairs) Computerised systems List of computerized systems in use in relation to PV (not just the global safety database ) Table adapted from MHRA Symposium (2018), Changing the face of inspections
16 Common PSMF Inspection Findings PSMF Annex Inspection finding details Annex B - Organisational Structure Not all contracts and agreements included (e.g. missing service providers or commercial agreements) Roles under taken and the concerned product(s)and territories not clearly described Annex C - Sources of Safety Information Non-EU affiliates and med info services not included If a list of studies is included it is not complete PSPs not considered
17 Common PSMF Inspection Findings cont. PSMF Annex Inspection finding details Annex F - PV System Performance Metrics presented not accurate (e.g. delays in PSUR submission not taken into account) Metrics provided were not up-to-date Metrics not prepared using all relevant information (e.g. variation submission timeliness for updates to the SmPC did not include all variations submitted) Annex G - Quality System Not all audits included in the list of audits completed Annex H- Products List not up-to-date Non-EU territories where the product is authorised/marketed not included Marketing status of products authorised in the EU not indicated
18 Common PSMF Inspection Findings cont. Sources of Safety Data PSMF Main body Inspection finding details This section of the PSMF did not include all third party arrangements including outlicensing partners, distributors and pharmacovigilance vendors PV Processes A description of the process, data handling and records for the performance of pharmacovigilance was not included in the main body PV System Performance No performance indictors described in the PSMF No associated targets relevant to the performance indicator
19 Common PSMF Inspection Findings cont. PSMF Main body Inspection finding details Quality System Notes and CAPAs associated with significant audit findings and quality system deviations were contained within the annexes and not within the main body. Not all significant audit findings and quality system deviations included in the PSMF. In some instances no deviations are included. CAPAs associated with significant findings not included and no due date for CAPA closure specified. List of scheduled audits not included.
20 Inspection readiness PSMF To inform risk assessment, scope and for preparation Complete and accurate, whenever requested / submitted Advance document requests To address gaps in the PSMF, to allow inspectors to refine the scope of specific areas and prepare Expect to provide documents from inspection announcement, and before on-site dates Planning /Agenda discussions To clarify scope and ensure that facilities/ people will be available Be prepared to discuss the contribution of third parties, relevant staff and logistics Document provision Records and information to navigate the system and evidence of compliant activity Discuss, rather than infer, be prepared to provide records, increasing can be remotely inspected MHRA Symposium (2018), Changing the face of inspections
21 Summary April 2017-March 2018, the MHRA conducted 22 inspections. April 2016 to March 2017, the MHRA conducted a total of 37 pharmacovigilance inspections; this is an increase of two inspections compared to the previous year. The 37 inspections conducted approximately 35% of these inspections were of MAHs/ organisations that had not previously undergone a MHRA pharmacovigilance inspection. The largest number of inspections were routine re-inspections (15 in total, 41%). Six critical findings were reported during April 2016 to March major findings were reported during this period, with 36 out of the 37 inspections conducted resulting in at least one major finding being reported. The largest proportion of major findings for a specific topic area was in relation to the quality system and quality assurance activities.
22 Summary cont. 84 minor findings were identified during the reporting period. Largest proportion of minor findings was in relation to the PSMF. The topic areas representing the largest proportion of inspection findings in this period are associated with the quality system and quality assurance activities, signal management, maintenance of the PSMF and maintenance of reference safety information. The PSMF is an essential tool used in inspection planning. It can also be used to help MAHs maintain oversight of the performance of their system and aid in audit planning. The PSMF is also a source of recurring inspection findings as detailed in this presentation and may be a reflection of wider system failings.
23 GROUP DISCUSSION What have been your experiences from audits or MHRA inspection findings in relation to the PSMF? What systems or processes have you implemented in your department to improve PSMF maintenance? What challenges have you experienced in the maintenance of the PSMF?
24 Glossary Inspection finding definitions Critical: a deficiency in pharmacovigilance systems, practices or processes that adversely affects the rights, safety or well-being of patients or that poses a potential risk to public health or that represents a serious violation of applicable legislation and guidelines. Major: a deficiency in pharmacovigilance systems, practices or processes that could potentially adversely affect the rights, safety or well-being of patients or that could potentially pose a risk to public health or that represents a violation of applicable legislation and guidelines. Minor: a deficiency in pharmacovigilance systems, practices or processes that would not be expected to adversely affect the rights, safety or well-being of patients. MHRA GPvP Inspection Metrics: April 2016 March 2017
25 Glossary cont. Inspection type definitions UK routine inspection (initial) this comprises inspections performed according to the national inspection programme and where it is the first MHRA pharmacovigilance inspection of the MAH. UK routine inspection (re-inspection) this comprises routine reinspections of MAHs under the national inspection programme. UK triggered - these inspections are performed under the national inspection programme and are triggered by either previous critical findings, requests from other MHRA divisions or as a result of other intelligence. CHMP triggered inspections requested by the CHMP in response to a specific trigger. MHRA GPvP Inspection Metrics: April 2016 March 2017
26 References MHRA GPvP Inspection Metrics Report: April 2016 March 2017 MHRA symposium (2018), Inspection finding trends
27 Questions
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage
More informationSOP-QA-30 V Scope
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Joanne Rodger, Senior R&D Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys,
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: GCP Inspection Procedures (MHRA) SOP Number: 15 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review
More informationStandard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes
Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP
More informationOther EU Activities Contributing to Harmonization of Labeling
Other EU Activities Contributing to Harmonization of Labeling Dr Laurent Brassart European Medicines Agency Medical Information Sector DIA Labeling Harmonisation 2011 Workshop October 13-14. 2011 Disclaimer
More informationEMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS
European Medicines Agency London, 21 August 2006 Doc. Ref. EMEA/214301/2006 EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS
More informationDIRECTIVES. (Text with EEA relevance)
L 238/44 DIRECTIVES COMMISSION DIRECTIVE (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of
More informationCHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS
CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of
More informationEU Regulatory Update & GMP Deficiencies. Bryan J Wright July 2017
EU Regulatory Update & GMP Deficiencies Bryan J Wright July 2017 Slide 1 PharmOut 2017 Outline Update on changes in EU GMP Guide Summary of GMP changes to the Guide Important details of changes over the
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationWorkshop for OIE national Focal Points for Veterinary Products November 2010, Johannesburg, South Africa. Presentation
Dr. Anja Holm Chair of CVMP, EMA Danish Medicines Agency Copenhagen, DK - Denmark anh@dkma.dk Overview of existing structures relevant for Veterinary Products Regional Structures: Europe European Medicine
More informationGPvP Symposium 2014: Welcome and Updates. 14 March 2014 Rebecca Stanbrook, Group Manager Inspections (GCP/GPvP/GLP)
GPvP Symposium 2014: Welcome and Updates 14 March 2014 Rebecca Stanbrook, Group Manager Inspections (GCP/GPvP/GLP) Agenda Housekeeping The MHRA Welcome The Day Ahead The Technology 2 Housekeeping Restrooms
More informationLEAF Marque Assurance Programme
Invisible ISEAL Code It is important that the integrity of the LEAF Marque Standard is upheld therefore the LEAF Marque Standards System has an Assurance Programme to ensure this. This document outlines
More information(Legislative acts) REGULATIONS
31.12.2010 Official Journal of the European Union L 348/1 I (Legislative acts) REGULATIONS REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards
More informationMedication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski
Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions Scientific conclusions Between 29 September 2015 and 9 October 2015, the United States Food and Drug Administration (FDA) performed a Good Clinical Practice (GCP) inspection
More informationUpdate regarding PSUR and RMP for herbal and homeopathical medicinal products
Update regarding PSUR and RMP for herbal and homeopathical medicinal products Mag. Dr. Irmgard Resch Dept. Pharmacovigilance AGES-Gespräche 11.11.2014 www.basg.gv.at Österreichische Agentur für Gesundheit
More informationSTANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED. BY THE NNUH and UEA
STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED BY THE NNUH and UEA Version 1.0 Version date 13.12.2016 Effective date 13.12.2016 Number of pages 11 pages Review date November
More informationXOSERVE LIMITED SERVICES SCHEDULE FOR THE PROVISION OF NON-CODE USER PAYS SERVICES (REFERENCE NUMBER XNCUP(SS)06) DATED 20 INTRODUCTION
XOSERVE LIMITED SERVICES SCHEDULE FOR THE PROVISION OF NON-CODE USER PAYS SERVICES (REFERENCE NUMBER XNCUP(SS)06) DATED 20 INTRODUCTION 1 This services schedule forms part of the framework contract for
More informationBlanka Hirschlerová. EDQM CEP conference Prague, Czech Republic
1 Experience with CEPs from a European regulatory authority perspective Blanka Hirschlerová EDQM CEP conference Prague, Czech Republic 2012 STATE INSTITUTE FOR DRUG CONTROL Agenda 2 Agenda Introduction
More informationHolders of European Union marketing authorizations
PRAC Experience The legal framework The Pharmacovigilance legislation (Regulation No 1235/2010 and Directive 2010/84/EU) was adopted by the European Parliament and European Council in December 2010. The
More informationTERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY
TERMS AND CONDITIONS OF NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY FOR OBTAINING AND MAINTAINING ITS GLP CERTIFICATION BY A TEST FACILITY Document No.GLP-101 Version/Issue
More informationAGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)
AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION (Moscow, 23 December 2014) Member States of the Eurasian Economic Union, hereinafter referred
More informationPublic Assessment Report. Scientific discussion. Granon (Acetylcysteine) DK/H/2352/ /MR. Date:
Public Assessment Report Scientific discussion Granon (Acetylcysteine) DK/H/2352/001-002/MR Date: 25-06-2015 This module reflects the scientific discussion for the approval of Granon. The procedure was
More informationGLP Update and Hot Topics
GLP Update and Hot Topics RQA Annual Conference Mark Goodwin 9 Nov 2016 Introduction International GLP Updates OECD including MAD Agreement EC/ EMA US FDA & US EPA UK GLP Update MHRA MHRA GLP Deficiencies
More informationIndependent Assurance Statement by Bureau Veritas
Nestlé S.A. Independent Assurance of Compliance with the Nestlé Policy and Instructions for Implementation of the WHO International Code of Marketing of Breastmilk Substitutes in Kenya (May 2014) Independent
More informationPharmacovigilance Methods and Post-Authorisation Safety Studies
Pharmacovigilance Methods and Post-Authorisation Safety Studies Alex Dodoo Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance Accra, Ghana Objectives At the end of this module
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD
More informationCARIBX (UK) LIMITED. Environmental, Health and Safety Management System. Revision: 00 APRIL 2011
CARIBX (UK) LIMITED Environmental, Health and Safety Management System Revision: 00 APRIL 2011 Document Details and Issue Record Rev No. Details Date Author Checked Text 00 Draft 01/04/2011 CJMD Calcs
More informationDecentralised Procedure. Public Assessment Report. Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten. Lorazepam DE/H/4558/ /DC
Decentralised Procedure Public Assessment Report Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten Lorazepam DE/H/4558/001-002/DC Applicant: neuraxpharm Arzneimittel GmbH, Germany Reference Member State
More informationDarwin Marine Supply Base HSEQ Quality Management Plan
Darwin Marine Supply Base HSEQ Quality Management Plan REVISION SUMMARY Revision Date Comment Authorised 0 29.9.13 Initial input JC 1 12.1.15 General Review JC 2 3 4 5 6 7 8 9 Revision Log Revision No
More informationSingle market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations Brussels,
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 08/03/2018 n/a
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationSwitzerland - still a special country?
5 th Pharmacovigilance Forum GLC Switzerland - still a special country? Tips for an successful Pharmacovigilance Inspection Dr. Doris Taeschner, Boehringer Ingelheim (Schweiz) GmbH 2 nd March 2017 Berlin
More informationThe European Medicines Agency (EMA)
The European Medicines Agency (EMA) Nathalie Bere Patient Relations Public Engagement Department EMA Training Day 29 November, 2016 An agency of the European Union What is the European Medicines Agency
More informationPGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne
Public consultation on Delegated Act on Post-Authorisation efficacy studies PGEU RESPONSE INTRODUCTION The Pharmaceutical Group of the European Union (PGEU) is the association representing community pharmacists
More informationHUD s Updates to the Lead Requirements CHHC ANNUAL MEETING DAY 2 TRAINING
HUD s Updates to the Lead Requirements CHHC ANNUAL MEETING DAY 2 TRAINING 1.24.2017 Agenda Goals and Outcomes of the Meeting Refresher on Existing Lead Safe Housing Rule and Lead Disclosure Rule Regulatory
More informationOUR VISION OUR MISSION
Health Canada Santé Canada Your health and safety... our priority. Votre santé et votre sécurité... notre priorité. INSPECTORATE PROGRAM ANNUAL INSPECTION SUMMARY REPORT 2012 2013 22 OUR VISION To be a
More informationWHAT DO MANUFACTURERS AND IMPORTERS HAVE TO DO TO PREPARE FOR EU MEMBERSHIP?
WHAT DO MANUFACTURERS AND IMPORTERS HAVE TO DO TO PREPARE FOR EU MEMBERSHIP? pharmaceutical regulatory affairs consulting and education www.rapharm.eu Vesna Koblar, MD. PhD. EU28: Science, Medicines, Health
More informationCHAPTER 3. Union Referral Procedures MAY 2014
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Brussels, Revision May 2014 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation
More informationGuideline on good pharmacovigilance practices (GVP)
19 April 2013 EMA/169546/2012 Guideline on good pharmacovigilance practices (GVP) Module X Additional monitoring Draft finalised by the Agency in collaboration with Member States 25 May 2012 Draft agreed
More informationIndependent Assurance Statement by Bureau Veritas
Nestlé S.A. Independent Assurance of Compliance with the Nestlé Policy and Instructions for Implementation of the WHO International Code of Marketing of Breastmilk Substitutes in Pakistan (August 2015)
More informationATMPs & EU GMP Update. Bryan J Wright July 2017
ATMPs & EU GMP Update Bryan J Wright July 2017 Slide 1 PharmOut 2017 Outline ATMPs What they are? Why are we looking at this subject? The Licensing position of ATMPs and use of PRIME ATMPs and GMP Inspections
More informationEU safeguards contribution to the global nuclear non-proliferation regime. Safeguards implementation in the European Union
2015 Review Conference of the Parties to the Treaty on the Non-Proliferation of Nuclear Weapons 5 May 2015 NPT/CONF.2015/WP.55. Original: English New York, 27 April-22 May 2015 EU safeguards contribution
More informationQ&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015
Proposal in response to EFPIA paper of 3 rd October 2014 EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Presented by Sabine Brosch (EMA) and Anja van
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION
More informationGuideline on the processing of renewals in the centralised procedure
14 July 2016 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation December 2000
More informationOverview Internal review
Overview Internal review Presentation title: QRM, It s not all about the assessment Track title: Day 1, Session 2 Speaker: Seamus Orr Date / Time: 10 August 2015, 14.30 15.00 Time allotted: 30 minutes
More informationKEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE
RNI Conseil 2017 Tous droits réservés Toute reproduction interdite sans l'autorisation de l'auteur. KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE Anne Laure TARDY, PhD
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Site Initiation SOP-RES-010 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Rachelle
More information(Invented) name Strength. Leflunomide Apotex 10 mg Tablet Oral use. Leflunomide Apotex 20 mg Tablet Oral use
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states 1 Member State EU/EEA Marketing authorisation
More informationPIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 040-1 3 Appendices 1 January 2019 PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PIC/S January 2019 Reproduction
More informationORDER of the Minister of Health No. 269/2017 of 14 March 2017 on mandatory provision of medicinal product adequate and continuous supplies
ORDER of the Minister of Health No. 269/2017 of 14 March 2017 on mandatory provision of medicinal product adequate and continuous supplies ISSUING BODY: The Ministry of Health published in: the Official
More informationChanging practice to support service delivery
Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction
More informationAnnual report on UK local authority food law enforcement 1 April 2015 to 31 March 2016
Annual report on UK local authority food law enforcement 1 April 2015 to 31 March 2016 TABLE OF CONTENT 1. Introduction... 2 2. Summary of key findings... 4 3. Data return levels from local authorities...
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 18/08/2017 SmPC and PL. 24/05/2017 SmPC, Annex II, Labelling
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 10.12.2008 COM(2008) 664 final 2008/0257 (COD) Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending, as regards pharmacovigilance
More informationChallenges for U.S. Attorneys Offices (USAO) in Opioid Cases
Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being
More informationCommunication and Information Sharing Agreement. between. The Care and Social Services Inspectorate Wales. and
Communication and Information Sharing Agreement between The Care and Social Services Inspectorate Wales and The Older People s Commissioner for Wales Page 1 of 12 1. Revision history and approval This
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationStandard operating procedure
Standard operating procedure Title: Preparation of an initial European Public Assessment Report (EPAR) for a human medicinal product following positive or negative opinion Status: PUBLIC Document no.:
More informationResearch on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version
Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File Division of Pharmaceuticals Department of Drug Registration Hou Renping Translation version Main
More informationEprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets. (Eprosartan mesilate) PL 37222/
Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets (Eprosartan mesilate) PL 37222/0027-29 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Steps
More informationStandard operating procedure
Standard operating procedure Title: Early Notification System: procedure for advanced notification of emerging safety issues to EU regulatory network and international partners Status: PUBLIC Document
More informationThis follows similar work previously conducted by Bureau Veritas for Nestlé S.A. in other global operations.
Nestlé S.A. Independent Assurance of Compliance with the Nestlé Policy and Instructions for Implementation of the WHO International Code of Marketing of Breastmilk Substitutes in Colombia (May 2016) Independent
More informationDecentralised Procedure. Public Assessment Report. Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten
Decentralised Procedure Public Assessment Report Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten Pramipexole dihydrochloride monohydrate DE/H/4703/001-007/DC Applicant:
More informationTitle: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use)
European Medicines Agency Standard Operating Procedure Title: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use) PUBLIC Document no.: SOP/H/3182
More informationCHE8000 Major Research Project A. The Complementary Medicines Reforms and Its Impact to the Complementary Medicine Industry and the Consumer
CHE8000 Major Research Project A The Complementary Medicines Reforms and Its Impact to the Complementary Medicine Industry and the Consumer Completed by: Lina Karlina (ID: 2067226) Lina Karlina (2067226)
More informationIndustry s Perspective on the Status of Medical Device Regulations. FUNDISA Workshop 09 & 10 Oct Anele Vutha SAMED Regulatory Committee
Industry s Perspective on the Status of Medical Device Regulations FUNDISA Workshop 09 & 10 Oct 2014 Anele Vutha SAMED Regulatory Committee Today s Topics: 1. Medical Device Definition - Differences 2.
More informationCHAPTER 3. September 2007
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/SM D(2007) Revision September 2007 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing
More informationAUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE WITH QUALITY MANAGEMENT SYSTEM FOR PATIENT GROUP DIRECTIONS
AUDIT TOOL FOR DISPENSING SERVICES COMPILED BY: Lynn Morrison ISSUE 1 CHECKED BY: Colette Byrne NUMBER: ISSUE DATE: 01.12.07 SUPERSEDES: NEW REVIEW DATE: 01.12.09 AUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE
More informationGLP in the European Union Ecolabel detergents, GLP and accreditation
GLP in the European Union Ecolabel detergents, GLP and accreditation Maik Schmahl Brussels, 25/03/2010 Chemicals Unit Outline What is GLP? How has it developed? The role of the Member States, the European
More informationHealth & Safety, Edinburgh Napier University
Health & Safety, Edinburgh Napier University Version number 2.0 Version date October 2018 Review Date 1 : 1 or earlier if change in legislation or on risk assessment Approval/Authorised Signature Distribution
More informationGUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT MEMBER STATES
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 5 November 2008 ENTR/F/2/SF D(2008) 34957 GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON
More informationCentralized Procedure
Centralized Procedure CHMP/EMA Overview of CHMP Operations Anthony Humphreys Head of Regulatory, Procedural and Committee Support DIA European Regulatory Affairs Forum 01-02 June 2010 London, UK Disclaimer
More informationProcedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products
25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of
More informationBMA INFORMATION BULLETIN No. 23. International Safety Management (ISM) Code
BMA INFORMATION BULLETIN No. 23 International Safety Management (ISM) Code Guidance and instructions for Ship-owners, Managers, Masters, Bahamas Recognised Organisations and Bahamas Approved Inspectors
More informationDATE: August 17, Document Title: Amendment to PIN Regarding Affiliation Agreements of Community and Migrant Health Centers
98-24 DATE: August 17, 1998 Document Title: Amendment to PIN 97-27 Regarding Affiliation Agreements of ommunity and Migrant Health enters TO: ommunity Health enters Migrant Health enters Health are for
More informationRECOMMENDATION ADOPTED BY THE INTERGOVERNMENTAL COMMITTEE FOR THE NAGOYA PROTOCOL AT ITS FIRST MEETING
CBD Distr. GENERAL 21 July 2011 OPEN-ENDED AD HOC INTERGOVERNMENTAL COMMITTEE FOR THE NAGOYA PROTOCOL ON ACCESS TO GENETIC RESOURCES AND THE FAIR AND EQUITABLE SHARING OF BENEFITS ARISING FROM THEIR UTILIZATION
More information15. Procuring, processing and transporting gametes and
15. Procuring, processing and transporting gametes and embryos Version 6.0 On this page: : Extracts from the HFE Act Directions HFEA guidance: Documented procedures: general Patient selection and procurement
More informationCDER Compliance Update
CDER Compliance Update Donald D. Ashley, JD 22 nd Annual GMP by the Sea August 30, 2017 www.fda.gov www.fda.gov 2 Office of Compliance Structure Office of Compliance Office of Drug Security, Integrity
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationQuality, Safety and Sourcing in Unlicensed Medicines
Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?
More informationExcipient Risk Assessment
Excipient Risk Assessment Richard O Sullivan- GMP Inspector GMP Conference 7 February 2017 Dublin Content Background 1 Guidance 2 HPRA Expectations 3 07/02/2017 2 Excipient Risk Assessment-Why? 07/02/2017
More informationRE: CONSULTATION ON DRAFT - DRUG AND NATURAL HEALTH PRODUCTS RECALL GUIDE
January 14, 2019 Health Products Compliance and Enforcement Unit Regulatory Operations and Regions Branch Health Canada By email to: hc.hpce-cpsal.sc@canada.ca RE: CONSULTATION ON DRAFT - DRUG AND NATURAL
More informationRADIATION SAFETY POLICY. Controlled Document Number: Version Number: 3 Controlled Document Sponsor: Controlled Document Lead: Approved By:
RADIATION SAFETY POLICY CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 3 Controlled Document Sponsor: Controlled Document Lead: Approved By: Policy Health
More informationSupport to paediatric medicines development
Support to paediatric medicines development SME Info day Supporting innovative medicines development and early access Presented by Rocio Fernandez Human Medicines Research & Development Support Division
More informationManaging the risks of clinical trials: the MRC/MHRA approach
Managing the risks of clinical trials: the MRC/MHRA approach Sarah Meredith MRC Clinical Trials Unit at UCL UCL Institute for Clinical Trials and Methodology FCRIN Workshop, Hôpital Saint Louis, Paris
More informationCOMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES
COMPETENT AUTHORITY (UK) 10 EC MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES (CUSTOM MADE DEVICES) Updated March 2008 CONTENTS PAGE Introduction 3 Definition of dental
More informationREGULATORY CHALLENGES IN SOUTH AFRICA
REGULATORY CHALLENGES IN SOUTH AFRICA MEDICINES CONTROL COUNCIL SA Prof Peter Eagles Chairperson Medicines Control Council [Southern African Regional and International Symposium (SARI 2014)] 1 OUTLINE
More informationAKA Good Manufacturing Practice (GMP) Certification Program
AKA Good Manufacturing Practice (GMP) Certification Program Preamble The American Kratom Association (AKA) is establishing this program to assure the safety and integrity of kratom dietary supplements
More informationDeviations Inspection Observations & Issues to Consider for Achieving Compliance
Deviations Inspection Observations & Issues to Consider for Achieving Compliance Kevin O Donnell, Ph.D. Market Compliance Manager Irish Medicines Board IMB GMP & Market Compliance Information Day Dublin,
More informationSurvey results - Analysis of higher tier studies submitted without testing proposals
Survey results - Analysis of higher tier studies submitted without testing proposals Submission of higher tier studies on vertebrate animals for REACH registration without a regulatory decision on testing
More informationRegulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices
Regulatory Framework for Medical Devices in South Africa 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Medicines and Related Substances Act, 1965 (Act 101 of 1965) Act 72 of 2008 and
More informationSafeguarding Annual Report
Safeguarding Annual Report 2016-17 Antony Heselton Head of Safeguarding and Prevent Lead 2016-2017 June 2017 1 Contents 1. Executive Summary. 3&4 2. Standards. 4&5 3. Action Plan Review. 5 4. Activity.
More informationNational Drug and Alcohol Treatment Waiting Times
National Drug and Alcohol Treatment Waiting Times 1 October 31 December 2017 Publication date 27 March 2018 A National Statistics publication for Scotland This is a National Statistics Publication National
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
The European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 December 2005 EMEA/357981/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON PROCEDURES
More informationPublic Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium
Public Assessment Report Scientific discussion Rabeprazolnatrium Torrent Pharma 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium DK/H/1819/001-002/DC This module reflects the scientific discussion
More informationRECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS
RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS Background The principal purpose of the Health Practitioners Competence Assurance Act 2003 (Act) is to protect public health
More informationValidation Introduction. Presented by John Montalto 27 March, 2013
Validation Introduction Presented by John Montalto 27 March, 2013 John Montalto Bachelor of Science Management Diploma >15 years of Industry Experience Consultant to United Nations various Government Regulatory
More information